Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02236273 · ClinicalTrials.gov registry record · NA
Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 956
- Enrollment target
NCT02236273: Completed NA study, sponsored by Columbia University.
NCT02236273 is a NA study that has completed, run by Columbia University. The registered enrollment target is 956 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02236273, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 956 participants
- Enrollment target
Study Summary
Emerging communication technologies, such as text messaging offer low-cost, scalable opportunities to improve health literacy and promote healthy behaviors, such as vaccination. While the investigators reported the success of text message vaccine reminders, effects were limited by their untailored approach. The trans-theoretical model of behavior change supports tailoring interventions to an individual's stage of decision-making. Human papillomavirus (HPV) is the most prevalent sexually transmitted virus in the U.S. and can lead to genital warts, and cervical, anal and penile cancer. The three-dose vaccine is 90-100% efficacious. Minorities are at greatest risk for such cancers but have low HPV vaccine completion rates. Limited health literacy regarding the vaccine can affect series completion. The investigators will compare the effects of enhancing text message vaccination reminders with interactive, vaccine health literacy-promoting information tailored to vaccine decision making-stage on HPV vaccine series completion. The effects of these messages represent a new paradigm in interactive health communications.
Primary Outcome
receipt of 3 doses of HPV vaccine by 12 months after initiation
Interventions
- BEHAVIORAL Conventional text message reminder
- BEHAVIORAL Enhanced text message reminders
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 956 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-12 |
| Phase | NA |
What the finished NCT02236273 record still lists
NCT02236273 is an interventional study that assigns participants to a tested intervention. The registered 956 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 2 interventions - of which Conventional text message reminder is the first listed.
NCT02236273 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02236273 about?
NCT02236273 is a clinical study titled "Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents". Emerging communication technologies, such as text messaging offer low-cost, scalable opportunities to improve health literacy and promote healthy behaviors, such as vaccination. While the investigators reported the success of text message vaccine reminders, effects were limited by their untailored a...
What is the current status of trial NCT02236273?
This trial is currently completed. It is a NA study. The enrollment target is 956 participants. The study started on 2014-12. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02236273?
The interventions under investigation include: Conventional text message reminder (BEHAVIORAL), Enhanced text message reminders (BEHAVIORAL).
Who is sponsoring clinical trial NCT02236273?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02236273's enrollment target sits among peer trials
956 123rd of 2000 higher than 1,878 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06225596 · 956 participants · Phase 2
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
- NCT06259669 · 958 participants
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia